Key Highlights

  • Third quarter net loss was USD 208.4 million, or USD 0.26 per share, against USD 231.8 million, or USD 0.31, a year earlier, while the nine-month net loss was USD 613.5 million.
  • Summit Therapeutics (NASDAQ:SMMT) closed a USD 2.0 billion gross Equity Investment from AstraZeneca on October 5, 2026, issuing Class A convertible preferred stock convertible into about 109.0 million common shares.
  • The FDA set a goal action date of November 14, 2026 for the ivonescimab BLA, and noted that a statistically significant overall survival benefit is necessary to support Marketing authorization.
  • Cash and cash equivalents were USD 150.8 million and short-term investments USD 479.0 million on September 30, 2026, and nine-month operating cash use totaled USD 423.2 million.

AstraZeneca Preferred Stock Deal Reshapes the Funding Picture

Summit Therapeutics (NASDAQ:SMMT) filed its Quarterly Report on November 4, 2026. On September 28, 2026 it agreed to sell about 108,955 shares of Class A convertible preferred stock to AstraZeneca at USD 18,356.14 each, each convertible into 1,000 common shares at USD 18.3561. The sale closed on October 5, 2026 for USD 2.0 billion before issuance costs. Conversion needs antitrust Waiting Period expiry and Shareholder approval to add 1.0 billion authorized common shares. With the proceeds, management concluded its cash covers at least 12 months of operating needs. Under the agreement the company also agreed to register the resale of the conversion shares within 60 days of closing. The deal brings a large new holder onto the register, which is a different funding route from the at-the-market sales used earlier in the year.

Loss Narrows on Lower G&A but R&D Keeps Climbing

Research and development expense rose to USD 169.1 million from USD 131.1 million, while general and administrative expense fell to USD 45.5 million from USD 103.1 million. Total operating expenses were USD 214.6 million versus USD 234.2 million, and other income was USD 6.2 million. Nine-month general and administrative expense was USD 170.8 million against USD 479.1 million. The company develops ivonescimab, a cancer drug candidate, and its accumulated Deficit reached USD 2.9 billion. It also sold 6.2 million shares through an at-the-market program in the quarter for USD 92.8 million net, with about USD 354.3 million of capacity left.

November 14 FDA Date and the Overall Survival Question

The BLA seeks approval of ivonescimab plus chemotherapy in EGFR-mutated non-small cell lung cancer. The company says the HARMONi study lacked a statistically significant overall survival benefit, and the FDA noted that progression-free survival results may not be sufficient. Management still believes the data show a favorable benefit-risk profile. HARMONi-3, a Phase III trial against pembrolizumab regimens, has completed enrollment. Risks include the FDA decision, dilution from conversion and continued losses, and the company states that it will need more Capital until it can generate substantial revenue. Nine-month Research and Development expense was USD 459.5 million against USD 390.4 million. Cash plus short-term investments were USD 629.8 million before the deal (calculated). The filing gave no stock price information.

Where Things Stand

The company raised the money through a USD 2.0 billion preferred stock sale to AstraZeneca, which closed after quarter end and extends its funding runway while losses continue near USD 200 million a quarter. Summit Therapeutics (NASDAQ:SMMT) still faces the November 14, 2026 FDA goal date, where the survival question is central, and eventual conversion would add about 109.0 million common shares.